about
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's DiseaseGenetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance.Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.An Old Challenge with New Promises: A Systematic Review on Comprehensive Geriatric Assessment in Long-Term Care Facilities.Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders.Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?Emerging biomarkers and screening for cognitive frailty.Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer's Disease and Late-Life Cognitive Disorders: A Systematic Review.Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry.Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging.Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging.Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset.Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline.Psychopathological profile and health-related quality of life (HRQOL) in patients with hepatocellular carcinoma (HCC) and cirrhosis.Klotho Gene and Selective Serotonin Reuptake Inhibitors: Response to Treatment in Late-Life Major Depressive Disorder.Cognitive frailty: a potential target for secondary prevention of dementia.Tau aggregation inhibitors: the future of Alzheimer's pharmacotherapy?Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer's Disease.Metabolic syndrome: differences between psychiatric and internal medicine patients.Executive Dysfunction Detected with the Frontal Assessment Battery in Alzheimer's Disease Versus Vascular Dementia.Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy.High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention.Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association.Genetics of tailored medicine: Focus on CNS drugsNutritional Interventions and Cognitive-related Outcomes in Patients with Late-life Cognitive Disorders: A Systematic ReviewSocial Dysfunction in Older Age and Relationships with Cognition, Depression, and Apathy: The GreatAGE StudyHydroxytryptamine transporter gene-linked polymorphic region (5HTTLPR) is associated with delusions in Alzheimer's diseaseNutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic ReviewPharmacotherapy for the treatment of depression in patients with alzheimer's disease: a treatment-resistant depressive disorderThe Age-Related Central Auditory Processing Disorder: Silent Impairment of the Cognitive Ear.Relationship between Inflammatory Food Consumption and Age-Related Hearing Loss in a Prospective Observational Cohort: Results from the Salus in Apulia StudyPromising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugsEpisodic memory and learning rates in amyotrophic lateral sclerosis without dementiaPharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipelineTime to test antibacterial therapy in Alzheimer's disease
P50
Q26739412-76B8DE04-3F15-4E9A-96E3-04210284DB44Q33533750-08024529-A718-40A8-899F-034E565B710FQ33533750-7D927D7D-65CD-413F-8047-5C11B1D56D81Q38590192-69ECDDB1-716A-4B36-A0B8-2ACE46CEC0D6Q38668611-7C3DC178-7FC7-49ED-920F-20C86931CC87Q38715233-2B21AFAC-D910-4B9B-9056-CD02DC893A34Q38885546-7C1FA8F5-99E1-4FB2-8415-78133B8ED0E2Q38915520-A5350DAB-0FC3-4A15-89D3-1ED1BFCEE846Q38966308-7B6446B0-CF20-44EE-BE54-3916B02270E9Q38975693-BBEE48CF-6032-4CAC-981E-6F672DD2986AQ39161884-C3EAEF00-19AE-409C-BF05-7471D011B956Q39428946-7FF73A3E-D646-4971-BCA3-702E3F0B7F2CQ40058836-3B80FB43-66E2-4A94-B16C-D3525A357A01Q40130422-F19B7E3A-6EBE-40FD-B7E6-777496DE0AF1Q40408989-D362232D-BBC0-4D12-92CF-0FE7887BC05BQ47450129-7E9AA138-C281-43AC-A427-ED7F4624FE81Q47567135-188C578D-F72D-4152-A3F5-4D559E42DB95Q47703267-50B176A8-F38D-4EF7-A7E5-7B14943BD27EQ47945856-11302550-824A-44E3-B9B1-CD9665B6486BQ48064738-AEE7981A-784D-4F94-883A-5F05B0323380Q48164466-84AEEF4A-3810-4018-B2E7-4FA95274D649Q48239696-033222BF-D0EC-44F5-961B-27D532523E37Q48253084-C16AC6D6-1AE1-41F7-8C79-BB45C7C3A9CFQ48422028-E0F346D2-FB54-4789-8CC4-A1FBB9E95E00Q50534644-89BAA4F3-AE4B-4B16-8B9F-C88D0C0AD9F3Q50632272-8FA4D648-F2E8-46AA-A414-EB9E20041E24Q50643343-67025D55-9D59-43F4-B58F-EB3E5D8E975EQ51760882-3E1FFF98-FC7E-492E-88F6-359020D6A7B5Q54018156-7E6ABCB5-B120-4391-AE34-C0BCD07AE0DFQ58005515-27AE1E8E-FD2E-4A20-83F2-4DD0E55328ADQ58617641-321C75D9-881C-4D47-8517-14475BFF30F5Q60050493-6329A2D9-17AB-4C5E-97A4-6B2E46BE0052Q61804653-AA6780E0-9A03-4CCD-8D5D-CE7E9E1B5C74Q64045182-6834A1A5-DD72-4F35-A097-D5800FE9DC33Q64045682-07D0CEEF-3C29-4BAC-975B-1E0DE333857CQ64993120-AAD6E9C4-9A89-4328-BD7B-93F10749EA52Q89657800-FE051DCC-F172-416A-9250-AFDC8CC9924BQ90011177-070F3700-D20A-41E8-8DA2-8E55439928B3Q90033437-E58FF004-AAFD-4257-BB85-2439350EDBD2Q90073998-179F9AEA-AD47-44A6-A34C-9DA6C77E7306
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Madia Lozupone
@ast
Madia Lozupone
@en
Madia Lozupone
@es
Madia Lozupone
@nl
type
label
Madia Lozupone
@ast
Madia Lozupone
@en
Madia Lozupone
@es
Madia Lozupone
@nl
prefLabel
Madia Lozupone
@ast
Madia Lozupone
@en
Madia Lozupone
@es
Madia Lozupone
@nl
P106
P1153
35753443500
P31
P496
0000-0002-1674-9724